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striato-frontal circuits (see Cools, 2006). These dorsal and ventral 
striato-frontal circuits have been implicated in different subfunc-
tions within the processing of rewards (Cools et al., 2001a, 2002; 
Packard and Knowlton, 2002).
Reward-based  performance  in  PD  patients  depends  on  the 
properties of the task used, and therewith on its underlying neu-
ral substrates. Perretta et al. (2005) showed that medicated PD 
patients in an early stage of the disease perform differently on 
two reward-based learning tasks, thus providing support for the 
assumption that those tasks rely on different striato-frontal circuits. 
The patients performed worse on the Iowa Gambling Task, a task 
that has been associated with the prefrontal cortex (e.g., Manes 
et al., 2002; Fellows and Farah, 2005), as compared to the Weather 
Prediction Task (WPT), which has been related to the striatum, 
especially the dorsal parts of the striatum (Knowlton et al., 1996). 
The performance on reward-based learning tasks also seems to 
be subject to the medication state PD patients are tested in (e.g., 
Swainson et al., 2000; Cools et al., 2001a,b, 2003), with Czernecki 
et al. (2002) however reporting no overall effect of dopaminergic 
treatment on their reward-based learning paradigms.
A common finding when testing PD patients in different medi-
cation states on reward-based tasks is the impaired performance of 
patients on medication as opposed to PD patients off medication 
on reversal learning tasks (Swainson et al., 2000; Cools et al., 2001a, 
IntroductIon
Therapy  with  the  dopamine  (DA)  precursor  levodopa  or  DA 
  agonists has proved successful in the treatment of motor symptoms 
associated with Parkinson’s disease (PD). However, the progres-
sive degeneration of dopaminergic neurons in PD not only affects 
motor abilities. Instead, consistent with the wide distribution of 
dopaminergic projection targets throughout the brain, dopaminer-
gic cell loss in PD patients is associated with a number of non-motor 
symptoms, e.g., symptoms relating to cognition, mood and motiva-
tion. The effects of dopaminergic drugs on cognitive symptoms are 
complex. While improvement has been reported in some domains, 
deteriorating effects or no changes have been found in others (for 
an overview, see Nieoullon, 2002; Cools, 2006).
Numerous cognitive and motivational processes have been linked 
to the brain reward system, which relies on the neurotransmitter DA. 
For instance, dopaminergic neurons projecting to the prefrontal cortex 
and the subcortical striatum have been shown repeatedly to be sensi-
tive to reinforcement in animals and humans (Schultz and Dickinson, 
2000; Bayer and Glimcher, 2005). Since PD is characterized by a loss of 
dopaminergic neurons, reward-based learning is one of the domains 
affected in PD (Knowlton et al., 1996; Shohamy et al., 2004).
Due to a characteristic progression of dopaminergic cell loss 
in the substantia nigra, DA depletion in PD progresses from dor-
solateral to ventromedial striatal structures and their associated 
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2007; Mehta et al., 2001). Reversal learning, as opposed to simple 
instrumental learning, is characterized by the challenge to switch 
behavior according to experimentally introduced changes in reward 
contingencies. The processing of such a behavioral adaptation dur-
ing reversal tasks has been shown to rely on ventral striato-frontal 
circuitry including the ventral striatum (e.g., Cools et al., 2002; 
Heekeren et al., 2007) and the orbitofrontal cortex (Rolls, 2000).
Medication-dependent  performance  differences  have  been 
explained with the “overdose hypothesis” (Gotham et al., 1988). Due 
to the progression of PD from dorsal to ventral structures (Cools, 
2006), the poorer performance on certain tasks while patients are 
on levodopa might arise from the fact that doses necessary to replete 
DA levels in the more severely affected regions (e.g., dorsal stria-
tum) are too high for less affected regions (e.g., orbitofrontal cor-
tex, ventral striatum), thus “overdosing” those regions of the brain 
and disrupting their function. Therefore, patients on dopaminergic 
medication would perform worse on tests that require the orbit-
ofrontal cortex or ventral striato-frontal circuits in general. Other 
studies generalized the “overdose hypothesis” to an “inverted U” 
shape relationship between DA levels and DA-depending function 
(Williams and Goldman-Rakic, 1995; Cools et al., 2001a; Mehta 
et al., 2001), with the optimal level depending on the nature of 
the function. This is consistent with reports that both insufficient 
and excessive DA levels can have adverse effects on cognition in 
experimental animals (Arnsten, 1998).
More recently, Frank and colleagues provided a more detailed 
mechanistic account of the DA “overdose hypothesis” (e.g., Frank 
et al., 2004). According to their theory, the critical prerequisite 
for basal ganglia-dependent learning is the availability of a large 
dynamic range in DA release: the discrimination between outcome 
values of different responses is only possible if the DA signal is 
able to increase or decrease substantially from its baseline levels. 
Therewith, they tie in with previous reports about rewards being 
connected with phasic DA bursts, whereas omission of rewards or 
punishments are connected with dips in DA (Schultz, 2006).
To investigate such an “inverted U” shape relationship which 
assumes both beneficial and detrimental (overdosing) dopamin-
ergic effects, within-subject designs are particularly useful. More 
recently,  a  few  studies  have  applied  within-subject  designs  to 
allow for group comparisons that are not influenced by differ-
ences between the groups other than the dopaminergic state (e.g., 
Czernecki et al., 2002; Moustafa et al., 2008a,b; Rutledge et al., 
2009). However, in addition to studying the effects of dopaminergic 
medication on reward-based performance, we were also interested 
in investigating to what extent the nature of the stimulus-reward 
associations within a task would have an effect on the performance 
of PD patients. In the present study, we therefore examined the 
combined effects of levodopa withdrawal and an experimentally 
imposed difference in reward contingencies by testing PD patients 
on two distinct reward-based learning tasks: a simple instrumental 
learning task characterized by constant reward contingencies and 
a reversal learning task characterized by dynamic reward con-
tingencies. PD patients on levodopa monotherapy were assessed 
twice, once on and once off their medication. We deliberately 
studied only patients on levodopa monotherapy who were not 
taking any other antiparkinsonian medication (e.g., DA agonists). 
Due to the differing pharmacological properties of levodopa and 
DA agonists, we deem it important to separately investigate the 
  influence of those medication groups on feedback-based tasks. To 
our knowledge, comparably few studies of reward-based behavior 
have examined patients treated with levodopa only. Therefore, with 
this study, we hope to shed some more light on the influence of 
levodopa on two reward-based tasks that differ in their stimulus-
reward contingencies. We hypothesized that PD patients off levo-
dopa (as compared to their respective performance on medication) 
would perform worse on the simple instrumental learning task 
characterized by constant reward contingencies and assumed to 
involve mainly dorsal striato-frontal circuits (for studies that have 
linked instrumental learning to the dorsal striatum, see Yin et al., 
2004; Kimchi et al., 2009), but that they would perform better on a 
reversal learning task with changing reward contingencies, which is 
assumed to rely on ventral striato-frontal circuits (e.g., Rolls, 2000; 
Cools et al., 2002; Heekeren et al., 2007). In line with our hypoth-
esis, we found a double dissociation between task performance and 
medication state suggesting that performance differences relate 
to a differential influence of levodopa on reinforcement learning 
depending on task-specific reward contingencies and underlying 
striato-frontal circuits.
MaterIals and Methods
subjects
Twenty patients with mild idiopathic PD were recruited from the 
neurological outpatients’ clinic of the Charité University Hospital, 
Campus Benjamin Franklin, Berlin, Germany. All patients were 
diagnosed by a neurologist and met the UK Brain Bank crite-
ria. Inclusion criteria were levodopa monotherapy (i.e., no con-
current therapy with DA agonists) and the ability to be tested 
both on medication (under the therapeutic effect of levodopa) 
and off medication (after abstaining from levodopa for at least 
12 h). Patients were excluded if they had a significant history of 
any other neurological or psychiatric illness, if their modified 
Hoehn and Yahr stage (Hoehn and Yahr, 1967) was higher than 
three and if they showed signs of a clinical depression (as meas-
ured with Beck’s Depression Inventory (Beck et al., 1961), BDI 
scores > 16) or dementia (as measured with the Mini Mental State 
Exam (Folstein et al., 1975), MMSE scores < 25) in the medicated 
state. The Parkinson Neuropsychometric Dementia Assessment 
(PANDA, Kessler et al., 2006), an additional PD-specific dementia 
screening, was applied as well. On average, all groups achieved 
scores in the cognitively unimpaired range. Two patients achieved 
a score below 15 on the PANDA, in each case however only on one 
of their two assessments. We did not exclude those two patients 
from the study because the scores were obtained in opposed medi-
cation states (on medication for one patient, off medication for 
the other) and MMSE scores were in the normal range on both 
assessments. Additionally, patients were tested on the Unified 
Parkinson’s Disease Rating Scale (UPDRS, Fahn et al., 1987), on 
the Fatigue Severity Scale (FSS, Krupp et al., 1989) and on a ques-
tionnaire assessing patients’ quality of life (PDQ-39, Peto et al., 
1995). The patients had been diagnosed with PD around 1.7 years 
prior (±1.6) and reported noticing the first symptoms around 
4.3 years (±4.0) ago. The average dose of levodopa taken by PD 
patients was 553.3 mg (SD: 227.8 mg, range: 200–1100 mg/day). 
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The patient and control group were matched in regard to age 
(t = −0.058, df = 29, p = 0.299) and years of education (t = –1.146, 
df = 27, p = 0.262). See Table 1 for subjects’ details. The patient 
groups differed significantly from the control subjects only in 
regard to their Hoehn and Yahr (NC vs PD ON: t = 9.885, df = 14, 
p = 0.000; NC vs PD OFF: t = 10.269, df = 14, p = 0.000) and 
UPDRS scores (NC vs PD ON: t = 8.042, df = 17.8, p = 0.000; 
NC vs PD OFF: t = 9.801, df = 16.1, p = 0.000), but not on 
any of the other clinical measures (BDI, MMSE, PANDA, FSS: 
p > 0.0167).
Within the patient sample, seven patients were tested on medi-
cation first while eight patients were tested off medication first. 
They were therefore divided into two subgroups: the “ON first” 
subgroup (N = 7) and the “OFF first” subgroup (N = 8). Table 2 
states was the Unified Parkinson’s Disease Rating Scale (UPDRS, 
Fahn et al., 1987) score, which was significantly higher for patients 
off levodopa (t = 7.56, df = 12, p = 0.000). Against the background 
of the criteria used, five patients had to be excluded since they 
were not testable in the OFF state. Consequently, a total of 15 PD 
patients could be included in the study, six of whom were female. 
All of these patients came in for two assessments, once on and once 
off medication, with a 4-week interval in between.
Sixteen healthy elderly subjects (six female) without any history 
of neurological or psychiatric illness served as a control group. 
They were recruited from a database at the Max-Planck-Institute 
for Human Development, Berlin. This study was approved by the 
Research Ethics Committee of the Charité University Medicine 
Berlin and all participants gave written informed consent.
Table 1 | Descriptive statistics for normal control subjects (NC) and PD patients.
  NC (N = 16)   PD total (N = 15)   PD ON (N = 15)   PD OFF (N = 15)  
  Mean ± SD (range)  Mean ± SD (range)  Mean ± SD (range)  Mean ± SD (range)
Age  67 .75 ± 4.55 (62–78)  65.27 ± 8.14 (52–83)   
Years of education  15.50 ± 3.00 (11–22)  14.00 ± 3.95 (8–20)   
Hoehn and Yahr stage  0 ± 0.0    1.68 ± 0.64* (1–3)  1.96 ± 0.78* (1–3)
UPDRS score  2.00 ± 1.51 (0–6)    19.64 ± 7 .70* (10–33)  30.93 ± 11.01* (13–51)
BDI score  5.31 ± 2.98 (0–11)    6.93 ± 5.55 (0–16)  8.50 ± 7 .77 (0–32)
MMSE score  29.00 ± 1.00 (27–30)    28.64 ± 1.15 (27–30)  28.57 ± 0.94 (27–30)
PANDA score  25.43 ± 3.2 (18–29)    22.14 ± 4.9 (13–30)  21.71 ± 5.1 (14–28)
FSS score  3.15 ± 1.4 (1.0–4.8)    3.60 ± 2.0 (1.0–7 .0)  3.60 ± 1.9 (1.11–6.67)
PDQ score      29.93 ± 24.7 (2–88)  35.21 ± 28.5 (4–97)
*Significantly different from control subjects (p < 0.0167). BDI, Beck depression inventory; FSS, fatigue severity scale; MMSE, mini mental state examination; 
PANDA, Parkinson neuropsychometric dementia assessment; PDQ, Parkinson’s disease questionnaire; UPDRS, unified Parkinson’s disease rating scale; SD, standard 
deviation.
Table 2 | Group characteristics for ON-beginner and OFF-beginner subgroups.
  ON first Mean ± SD (range)  OFF first Mean ± SD (range)  t  df  p
Age  69.1 ± 7 .9 (59–83)  61.9 ± 7 .1 (52–69)  −1.874   13  0.084
Education in years  13.7 ± 5.0 (8.0–20.0)  14.3 ± 3.1 (11–20)  0.253  13  0.804
Years since diagnosis  1.9 ± 1.6 (0–4.0)  1.5 ± 1.7 (0–5.0)  −0.514  13  0.616
Years since first symptoms  5.6 ± 5.4 (0–14.0)  3.1 ± 2.0 (1–6.5)  −1.133a  7 .515  0.292
Daily levodopa dose in mg  607 .1 ± 300.6 (200–1100)  506.3 ± 156.8 (200–700)  −0.832  13  0.421
Hoehn and Yahr stage ON  2.1 ± 0.6 (1.0–3.0)  1.3 ± 0.4 (1.0–2.0)  −3.192  13  0.007b
Hoehn and Yahr stage OFF  2.7 ± 0.4 (2.0–3.0)  1.4 ± 0.4 (1.0–2.0)  −6.070  13  0.000
UPDRS score ON  23.4 ± 7 . 7(12–33)  15.4 ± 5.7 (10–26)  −2.322  13  0.037
UPDRS score OFF  37 .1 ± 10.2 (23–51)  24.5 ± 7 .7 (13–40)  −2.733  13  0.017
BDI score ON  10.1 ± 4.9 (2–16)  4.1 ± 4.7 (0–14)  −2.438  13  0.030
BDI score OFF  13.3 ± 9.5 (6–32)  4.9 ± 3.6 (0–9)  −2.334  12  0.038
MMSE score ON  28.5 ± 0.8 (28–30)  28.8 ± 1.4 (27–30)  0.418a  11.608  0.684
MMSE score OFF  28.3 ± 0.8 (27–29)  28.8 ± 1.0 (27–30)  0.812  12  0.433
PDQ score ON  46.5 ± 26.7 (5–88)  17 .5 ± 14.5 (2–37)  −2.618  12  0.022
PDQ score OFF  57 .3 ± 27 .7 (12–97)  18.6 ± 15.0 (4–45)  −3.380  12  0.005
FSS score ON  5.1 ± 2.0 (1.9–7 .0)  2.5 ± 1.2 (1.0–3.9)  −2.996  12  0.011
FSS score OFF  5.0 ± 1.8 (1.9–6.7)  2.6 ± 1.2 (1.1–4.9)  −2.491  11  0.030
aNumbers in italics represent tests, in which variances could not be considered as equal. bBold numbers represent significant differences (p < 0.05). BDI, Beck 
depression inventory; FSS, fatigue severity scale; MMSE, mini mental state examination; PDQ, Parkinson’s disease questionnaire; UPDRS, unified Parkinson’s 
disease rating scale; SD, standard deviation.Frontiers in Human Neuroscience  www.frontiersin.org  October 2010  | Volume 4  | Article 169  |  4
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task desIgn
Probabilistic reversal learning task with changing reward 
contingencies
This task is a modification of a task used in previous studies (see 
also Reischies, 1999; Marschner et al., 2005; Mell et al., 2005; Krugel 
et al., 2009). For a total of 228 trials, participants chose one out 
of four options presented simultaneously on a computer screen. 
Non-monetary feedback (5, 15, or 30 points) was presented after 
each choice. The participant’s objective was to collect as many 
points as possible. At a time, only one option was the maximally 
rewarded one. To make the task less predictable, the choice of this 
option led to the maximum number of points in 75% of trials only. 
After reaching a specified learning criterion (choosing the highest-
rewarded option in six out of eight consecutive trials), the reward 
contingencies changed so that another option became the highest-
rewarded one. In this task, the main measure of interest was the 
number of switches (“reversals”) achieved. The stimuli used did not 
elicit any one-sided preferences and were considered easily recog-
nizable in pre-tests with healthy controls. Additionally, they stayed 
at the same position throughout the experiment to keep working 
memory requirements low. The decision was carried out by pressing 
one of four buttons on the button box. The buttons were arranged 
in the same order as the stimuli on the screen. Each trial lasted a 
maximum of 4250 ms: the options were displayed for 2750 ms first, 
the subject then had to make a decision within the next 750 ms, and 
finally, the feedback was shown for 750 ms. If participants did not 
press one of the assigned buttons during that time, a hint appeared 
on the screen telling the subject that the response was given too 
slowly (“Leider zu langsam” – “Unfortunately too slow”).
Probabilistic instrumental learning task with constant reward 
contingencies
In each trial, two geometric figures were presented on a computer 
screen. For 30 trials in a row, the same two options were displayed 
and participants repeatedly chose from this pair of options to find 
out which option was the higher rewarded one. The positive rein-
forcement for which participants had to aim was a yellow smiley 
face. To make the task less predictable, the two options had differ-
ent pre-defined stochastic probabilities with which they led to this 
desired outcome: the target effectuated the smiley face in either 70, 
60, or 50% of all trials, whereas the distractor was always rewarded 
in only 40% of all trials. In those trials that were not rewarded with 
a smiley face, a red-colored sad face was shown. Participants knew 
in advance that each of altogether eight pairs of stimuli would be 
presented repeatedly over 30 trials, during which they would have 
to find out which option leads to the correct outcome (the smiley 
face) more frequently. The geometric figures used in this task were 
taken from the Rey Visual Design Learning Test (Rey, 1964) and 
modified at the Cognitive Neuroscience Lab at the University of 
Michigan. They were found to elicit no one-sided preferences when 
evaluated by healthy control subjects. All of the symbols were of 
the same color and varied only with respect to shape. To avoid 
side effects, the symbols changed sides randomly across the 30 
trials. Participants chose by pressing either the left or right button 
on a specially designed button box. Each trial lasted a maximum 
of 3450 ms: the options were displayed for 2250 ms first, then the 
shows group characteristics for the two patient subgroups. Patients 
for this study were recruited in a consecutive manner. Therefore, 
the patients in the two subgroups were not matched for parameters 
other than disease duration and years of education. Consequently, 
significant differences were found between the two subgroups 
with regard to Hoehn and Yahr stage, UPDRS, BDI, PDQ and 
FSS scores.
Procedure
Patients were tested at the time of day when they subjectively felt 
best, testing sessions for control subjects started at 9 am. After 
filling in screening tests for depression (BDI) as well as for fatigue 
(FSS) and patient’s quality of life in the patient sample, participants 
were seated at a 1.5-m distance from the presentation computer. 
They carried out four different tasks, two of which are reported 
here. To avoid sequence effects, task sequence was randomized 
across all subjects. There were regular breaks between the tasks 
during which instructions for the task to come were given. When 
participants had no further questions regarding the task, a test run 
was started. For both the instrumental and reversal task, picture 
stimuli in these test runs were different from the stimuli used in the 
actual experiment. For the task with constant reward contingen-
cies, a simple probabilistic instrumental learning task, participants 
had to complete at least one block of 30 test trials until one picture 
pair was recognized correctly. For the reversal learning task with 
changing reward contingencies, subjects had to pursue until suc-
cessfully achieving two reversals under probabilistic conditions to 
ensure that the concept of switching had been understood. Some 
subjects needed a little more practice than others before they 
grasped the switching concept. However, we believe that minor 
differences in practice time are justified in order to ensure that the 
instruction had been understood correctly and that performance 
differences in the actual task would not be based on misinterpret-
ing instructions. Participants made their decision by pressing the 
according button on a specially designed button box with four 
buttons that were arranged in a rhomboid shape (one at the top, 
one at the bottom, one on the right and one on the left side). 
For the probabilistic instrumental learning task, the upper and 
lower buttons were masked so that only the right and left buttons 
were available. When only two buttons were needed, participants 
were asked to use one hand only (their preferred hand). For the 
reversal learning task, however, participants were allowed to use 
both hands. To control for differences in motor skills due to the 
medication state, patients and control subjects had to carry out a 
finger-tapping task before the actual experiment started. During 
that task, participants had to press a specific button on the button 
box repeatedly with their right and left index finger, respectively, 
during 30 s each.
In the case of the patients, the routine described above was 
repeated in exactly the same way approximately 4 weeks later: task 
sequence and time of testing was the same as on the first assess-
ment; participants were given the same instructions and had to 
accomplish test runs for the tasks again. Standardization of the 
study procedure was given by means of standardized task instruc-
tions, obligatory test runs on both testing sessions and identical 
time of testing and task sequence for both sessions.Frontiers in Human Neuroscience  www.frontiersin.org  October 2010  | Volume 4  | Article 169  |  5
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Since patients were recruited in a consecutive manner and because 
significant differences with regard to Hoehn and Yahr stage, UPDRS, 
BDI, PDQ and FSS scores were found between the two subgroups as 
a consequence (see Table 2), a comparison between the subgroups 
may make it necessary to include covariates in the analyses. When 
including covariates into the analysis, only the scores assessed while 
on medication were used since the scores are correlated between 
the ON and OFF state. In addition, change scores between the OFF 
and ON state were compared to account for group differences in 
the extent of change from one state to another. The extent of change 
from the medicated to the unmedicated state was significantly greater 
for the “ON first” subgroup for UPDRS and PDQ scores. Therefore, 
the following covariates were included when calculating ANCOVA 
comparing the “ON first” and “OFF first” subgroups: Hoehn and 
Yahr stage (ON medication), UPDRS score (ON medication), BDI 
score (ON medication), PDQ score (ON medication), FSS score 
(ON medication), UPDRS change score (OFF–ON), PDQ change 
score (OFF–ON). Consequently, estimated marginal means were 
calculated as is usually the case when accounting for covariates.
Before calculating ANCOVAs, boxplots were generated to dis-
play distribution of the data. As suggested by Frigge et al. (1989), 
data values outside 1.5 IQR (inter-quartile range) were considered 
as outliers.
For exploratory comparisons between healthy control subjects 
and the patients in their respective medication states (ON and 
OFF), multiple independent-sample t-tests between the control 
group and the patient group as a whole (N = 15) in both its medi-
cation states (ON and OFF) were calculated. Differences between 
the patients on versus off medication (the whole group of patients 
on levodopa vs. the whole group off levodopa) were generally 
tested with paired t-tests (the prerequisite of normal distribu-
tion was fulfilled for all variables). All statistics were calculated 
using the Statistical Package for Social Sciences (SPSS® 15.0, SPSS 
Inc.) and MATLAB® programming software (The MathWorksTM, 
version R2007a). When calculating t-tests with unspecific hypoth-
eses, generally, an α-level of 5% was applied. However, because 
subject had to make a decision within the next 500 ms, and finally 
the feedback was shown for 700 ms. If participants did not press one 
of the assigned buttons during the decision time, a hint appeared on 
the screen telling the subject that the response was given too slowly 
(“Leider zu langsam” – “Unfortunately too slow”). Choices, reaction 
time, and number of missed trials were recorded. The main measure 
of interest in this task was the percentage of correct choices.
Both tasks were programmed with Presentation® software, version 
11.1 (Neurobehavioral Systems, Inc; Albany, CA/USA) and adminis-
tered on a 17” computer screen at a standard distance of 1.5 m from 
the subject’s eyes. Pre-tests were conducted with 25 healthy elderly 
controls to adjust experiment parameters according to the intended 
setup. We chose to administrate two separate tasks instead of just 
one task with several distinct phases of   stimulus-reward learning 
versus reversal learning in order to clearly separate the effects of con-
stant versus dynamic reward contingencies. While the instrumental 
learning task allowed us to study the performance on a task with 
constant reward contingencies over a total of 240 trials (8 blocks of 
30 trials), the reversal learning task allowed repeated switches in the 
reward contingencies with the final number of switches depending 
on the participant’s performance. See Figure 1 for the setup of the 
two reward-based learning tasks used in the study.
data analysIs
Since we were mainly interested in the influence of dopaminergic 
medication on reward-based learning, we focused the statistical 
analysis on comparing the performances across the two medica-
tion states. We calculated repeated measures analyses of covariance 
(ANCOVA) with session as repeated measures factor to investi-
gate interaction effects between the subgroups and testing sessions. 
Patients were divided into the subgroups “ON first” and “OFF first” 
for patients beginning on medication and patients beginning off 
medication, respectively. As half of the patients started on medica-
tion and the other half off medication, regression effects to or from 
the mean are unlikely to have had a significant impact on the results 
and therefore, they can be neglected as potential biasing factors.
FiGure 1 | Setup of the two reward-based learning tasks.Frontiers in Human Neuroscience  www.frontiersin.org  October 2010  | Volume 4  | Article 169  |  6
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Since our two patient subgroups, the OFF-beginners and the 
ON-beginners, differed significantly in several clinical parameters 
(see Table 2) due to the consecutive recruitment, we calculated an 
ANCOVA to ensure that the clinical differences would not mask a 
potential interaction effect of (sub)group × session. Unfortunately 
however, the number of degrees of freedom decreased consider-
ably due to the inclusion of covariates. Because the relevant out-
come of the ANCOVA was the interaction effect (which looks at 
the differential session effects within two separate subgroups) and 
not the main effect of group (which would be a between-subject 
comparison), one could argue that a comparison even without 
the inclusion of covariates may be justifiable. However, it should 
be noted that the comparison of two heterogeneous patient sub-
groups without controlling for covariates might mask potential 
effects of dopaminergic medication on reward-based perform-
ance. Therefore, calculation of an ANOVA without controlling for 
covariates will result in a higher number of degrees of freedom, 
but will also make it more likely that a potential effect might be 
masked. We calculated an additional ANOVA without covariates 
comparing the “OFF first” and “ON first” subgroups to allow for 
a higher number of degrees of freedom and to confirm whether 
our results would also hold true when differences between the 
two subgroups other than the dopaminergic state would not 
be controlled for in the form of covariates. Again, the relevant 
interaction group × session was significant (F(1, 12) = 8.268, 
p = 0.014, partial eta2 = 0.408). There were no main effects of 
group (F(1, 12) = 0.449, p = 0.515) or session (F(1, 12) = 1.435, 
p = 0.254). Homogeneity of the covariance matrices (Box-M-
Test = 5.153, F(3, 25920) = 1.407, p = 0.238) and equality of error 
variances (Levene’s test for reversals [session 1]: F(1, 12) = 0.740, 
p = 0.406, and for reversals [session 2]: F(1, 12) = 0.057, p = 0.815) 
was given for the ANOVA as well.
Table 3 shows group performances and simple group   comparisons 
between the control group and the PD patients (on and off levo-
dopa). The control group did not differ significantly from the PD 
of the problem of α-inflation when   calculating multiple t-tests, 
a Bonferroni-adjusted α of 1.67 was used when comparing three 
groups. Due to technical problems during acquisition of the data 
for the probabilistic instrumental learning task, data from 2 of 
the 16 control subjects had to be discarded. Therefore, 14 controls 
and 15 patients entered the analysis for this task.
results
ProbabIlIstIc reversal learnIng task wIth changIng reward 
contIngencIes
For the reversal learning task, two subjects (one PD patient and one 
control subject) were identified as statistical outliers (data values 
outside 1.5 IQR; Frigge et al., 1989) and had to be excluded from the 
analysis since the sample size was quite small and thus susceptible 
to deviations. As a consequence, the following results are based on 
14 PD patients and 15 control subjects.
Our main focus lay on the comparison of patients on and off 
dopaminergic medication. Therefore, we compared our two patient 
subgroups, the “ON first” group beginning on levodopa and the “OFF 
first” group starting off levodopa. We expected that the “OFF first” 
subgroup would achieve more reversals on their first session (i.e., while 
the patients were off medication) than on the second session (while 
they were on medication). The opposite was expected for the “ON 
first” subgroup, with less reversals expected on the first assessment 
(on medication) and more reversals on the second assessment (off 
medication). It is important to note that, in terms of the ANCOVA, 
the crucial result would be a significant interaction between group 
and session and not a significant main effect of the group. Since each 
of the two subgroups (ON first, OFF first) included patients that were 
tested both on and off levodopa, a main effect of the group would 
not be relevant as a sign of differences in the medication states. The 
interaction of group and session, however, makes it possible to draw 
conclusions about the effect of medication state on performance.
The results confirmed our hypotheses (see Figure 2). The signifi-
cant interaction (F(1, 4) = 302.483, p < .001, partial eta2 = 0.987) 
and the associated estimated marginal means show that perform-
ance on the probabilistic reversal task was indeed better for patients 
off medication.
Both subgroups achieved a similar number of reversals in the 
OFF state, irrespective of the session, in which they were assessed 
without medication. In the ON state, the “OFF first” subgroup 
achieved approximately two reversals more than the “ON first” 
subgroup. Since for this subgroup, the ON session was the sec-
ond assessment, it seems likely that a learning effect might have 
occurred across the two sessions on top of the effect of medica-
tion. For the ANCOVA, the main effect “session” was significant 
as well (F(1, 4) = 104.149, p = 0.001, partial eta2 = 0.963), suggest-
ing that there was indeed a learning effect over sessions for the 
reversal learning task. Homogeneity of the covariance matrices 
(Box-M-Test = 2.859, F(3, 433459) = 0.763, p = 0.515) and equal-
ity of error variances was given (Levene’s test for reversals [ses-
sion 1]: F(1, 11) = 1.579, p = 0.235, and for reversals [session 2]: 
F(1, 11) = 1.488, p = 0.248). There was no significant main effect 
of group (F(1, 4) = 0.049, p = 0.835). Also, simple effects of group 
tested for each session separately did not elicit any significant dif-
ferences between the two subgroups on either session (session 1: 
F(1, 4) = 2.163, p = .215; session 2: F(1, 4) = 1.060, p = 0.361).
FiGure 2 | Performance of ON-beginner (“ON first”) and OFF-beginner 
(“OFF first”) subgroups across sessions on the reversal learning task. 
Covariate-corrected estimated means of the number of reversals achieved are 
shown in boxes.Frontiers in Human Neuroscience  www.frontiersin.org  October 2010  | Volume 4  | Article 169  |  7
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Whereas  both  main  effects  (for  session  and  group)  were 
not    significant  (session:  F(1,  5)  =  1.347,  p  =  0.298;  group: 
F(1, 5) = 0.961, p = 0.372), the relevant interaction session × group 
yielded significance (F(1, 5) = 8.094, p = 0.036, partial eta2 = 0.618), 
thus supporting the hypothesis that patients on levodopa medica-
tion perform better on a simple instrumental learning task than 
patients off medication. Homogeneity of the covariance matrices 
(Box-M-Test = 4.095, F(3, 9784) = 1.109, p = 0.344) and equality 
of error variances was given (Levene’s test for percentage cor-
rect [session 1]: F(1, 12) = .068, p = 0.799, and for percentage 
correct [session 2]: F(1, 12) = 2.095, p = 0.173). At first glance, 
it might seem as if the significant group × session interaction 
is driven by an effect in the second session since the difference 
between the two subgroups appears very small in the first session. 
However, simple group effects tested for each session separately 
did not show significant differences between the two subgroups 
in either session (session 1: F(1, 5) = 0.404, p = 0.553; session 2: 
F(1, 5) = 4.259, p = 0.094).
For  the  instrumental  learning  task  with  constant  reward 
  contingencies, an ANOVA (no covariates, more degrees of free-
dom)  did  not  show  a  significant  group  ×  session    interaction 
(F(1, 13) = 0.104, p = 0.752). Main effects for group (F(1, 13) = 1.998, 
p = 0.181) or session (F(1, 13) = 0.385, p = 0.545) were also 
not significant.
Table 4 shows simple group comparisons between control sub-
jects and patients on and off levodopa. No significant differences 
between the performance of healthy controls and the performance 
of the PD group (medicated or unmedicated) were found.
reactIon tIMes, MIssed trIals and fInger-taPPIng task
Mean reaction times (see Table 5) and the percentage of missed 
trials (see Table 6) did not differ significantly between groups for 
any task. There were no significant differences between groups with 
regard to the finger-tapping task either (see Table 7), suggesting no 
marked impairment in elementary motor control.
Unexpectedly, the mean reaction times tended to be largest for 
the control group. On both tasks, controls took longer to decide 
by button press than PD patients both on and off medication. On 
average, PD patients on medication were the quickest to respond. 
However, none of the differences in reaction time between all three 
groups was significant.
correlatIon analysIs of levodoPa dosage wIth task 
PerforMance
The patients differed with regard to their prescribed levodopa dose. 
The lowest dosage taken was 200 mg/day whereas the highest was 
1100 mg/day. However, the daily levodopa dosage (in mg) of PD 
patients was not found to correlate with either the percentage of 
correct choices in the simple probabilistic learning task (N = 15; 
ON: r = 0.158, p = 0.574; OFF: r = −0.008, p = 0.978) or the number 
of reversals achieved on the reversal task (N = 14; ON: r = -.254, 
p = 0.381; OFF: r = −0.131, p = 0.655; see Figure 4).
dIscussIon
This study aimed at investigating the role of DA in reward-based learning 
depending on whether reward contingencies are constant or dynamic. 
Learning can be considered as an ongoing process of trying to achieve 
patients in any of the two medication states. Interestingly though, 
patients achieved a significantly higher number of reversals off 
medication compared to their performance on medication. This 
confirms the results of the analyses of (co)variance, which showed 
subgroups in their respective OFF states (first session for “OFF first” 
subgroup, second session for “ON first” subgroup) to perform bet-
ter than in their respective ON states.
ProbabIlIstIc InstruMental learnIng task wIth constant 
reward contIngencIes
For the instrumental learning task with constant reward contingen-
cies, we expected that the “ON first” subgroup would perform better 
on their first session (i.e., while the patients were on medication) 
than on the second session (while they were off medication). The 
opposite was expected for the “OFF first” subgroup, with a poorer 
performance expected on the first assessment (off medication) and 
better performance on the second assessment (on medication). As 
in the analysis of the reversal learning task, this effect should result 
in a significant group × session interaction in the ANCOVA. Again, 
the results confirmed our hypotheses (see Figure 3).
Table 3 | Number of reversals achieved on the reversal learning task.
  Group  t-test for equality 
  statistics  of means
  N  Mean  SD     t  df  Sig.  
              (two-tailed)
NC  15  10.73  2.865  NC vs. ON  −0.191  27  0.850
PD off  14  13.14  3.695  NC vs. OFF  1.899  27  0.068
PD on  14  10.50  3.920  ON vs. OFFa  3.137  13  0.008b
aPaired samples t-test.
bSig. difference, p < 0.0167 .
FiGure 3 | Performance of ON-beginner (“ON first”) and OFF-beginner 
subgroups (“OFF first”) across sessions on the instrumental learning 
task. Covariate-corrected estimated means of percentage of correct choices 
are shown in boxes.Frontiers in Human Neuroscience  www.frontiersin.org  October 2010  | Volume 4  | Article 169  |  8
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Table 6 | Mean percentage of missed trials across both reward-based 
learning tasks.
  Group   t-test for equality 
  characteristics  of means 
  N  Mean  SD    t  df  Sig. 
              (two-tailed)
iNSTruMeNTal learNiNG TaSK
NC  14  3.60  3.20  NC vs. ON  1.033  27  0.311
PD ON  15  6.31  9.29  NC vs. OFF  1.141  17 .894  0.269
PD OFF  15  6.36  8.76  ON vs. OFF  −0.046  14  0.964
reverSal learNiNG TaSK 
NC  15  2.89  3.23  NC vs. ON  −0.116  27  0.909
PD ON  14  2.76  3.17  NC vs. OFF  0.300  27  0.767
PD OFF  14  3.29  3.85  ON vs. OFF  0.854  13  0.409
Table 4 | Percentage of correct choices on the instrumental learning task 
with constant reward contingencies.
  Group  t-test for equality 
  statistics  of means 
  N  Mean  SD     t  df  Sig. 
              (two-tailed)
NC  14  68.493  14.017  NC vs. ON  1.802  27  0.083
PD on  15  60.068  11.081  NC vs. OFF  −2.185  27  0.038
PD off  15  59.048  8.856  ON vs. OFFa  −0.374  14  0.714
aPaired samples t-test.
Table 5 | Mean reaction times and t-test results for the reward-based 
learning tasks in healthy controls (NC) and PD patients on levodopa 
(ON) and off levodopa (OFF).
  Group  t-test for equality 
  characteristics  of means 
  N  Mean  SD    t  df  Sig. 
              (two-tailed)
iNSTruMeNTal learNiNG TaSK
NC  14  586.6  75.9  NC vs. ON  −1.953  27  0.061
PD ON  15  516.4  112.7  NC vs. OFF  −1.225  27  0.231
PD OFF  15  545.8  100.7  ON vs. OFF  1.031  14  0.320
reverSal learNiNG TaSK 
NC  15  512.9  72.2  NC vs. ON  −1.085  27  0.287
PD ON  14  479.0  95.6  NC vs. OFF  −0.419  27  0.679
PD OFF  14  500.3  89.6  ON vs. OFF  0.945  13  0.362
ronment and can be illustrated in a reversal learning task, a task that 
requires participants to adapt their behavior according to switches in 
the rewarding properties of the choices at hand.
It is well known that feedback-based learning is affected by PD 
(e.g., Knowlton et al., 1996). However, different accounts have been 
given depending on the nature of the feedback-based task used 
(e.g., Perretta et al., 2005) and the medication status of the patients 
studied (e.g., Cools et al., 2001a). Tying in with those findings, we 
set out to evaluate whether the medication state in PD patients has 
a differential effect depending on the stimulus-reward properties 
of two feedback-based tasks.
We  compared  the  performance  of  PD  patients  on  and  off 
levodopa on two reward-based learning tasks that differ in their 
stimulus-reward contingencies. Whereas the instrumental learning 
task required participants to learn which of two options elicited 
higher rewards, the reversal learning task did not primarily examine 
option-outcome association learning but mainly the unlearning 
of those associations against the background of changing reward 
contingencies. We found a double dissociation between patients’ 
medication state and performance on the reward-based learn-
ing tasks: Patients on medication achieved a higher percentage 
of correct choices on the simple option-outcome association task 
characterized by constant reward contingencies, which, much like 
habit learning in animals, would be expected to primarily rely on 
dorsal striatal structures (Yin et al., 2004; Seger, 2006; but see De 
Wit et al., 2010). Conversely, when patients were off medication, 
they performed better on a reversal learning task with dynamic 
reward contingencies, i.e., they achieved more reversals than on 
medication. Reversal learning, unlike simple instrumental learning, 
requires unlearning of previously installed stimulus-reward asso-
ciations, which crucially depends on ventral striato-frontal circuits 
including the ventral striatum and the orbitofrontal cortex (Rolls, 
2000; Cools et al., 2007).
Our analysis showed a very strong effect of medication on reversal 
learning, which was not only detected by means of a paired t-test 
between all patients on levodopa and all patients off levodopa, but 
also by means of a repeated measures analysis of variance across 
two (clinically heterogeneous) patient subgroups. The relevant 
interaction between subgroup (OFF-beginners vs. ON-beginners) 
and time of testing (first vs. second session) was significant, both 
when controlling for differences between the patient subgroups by 
including covariates and also across the heterogeneous subgroups 
(without covariates). For the instrumental learning task with con-
stant reward contingencies, the effect of levodopa was less distinct. 
For this task, to show a significant interaction between subgroup 
and time of testing the covariates needed to be included in the 
analysis of (co)variance. This suggests that the differences between 
the two patient subgroups (ON-beginners vs. OFF-beginners) on 
clinical scales like the UPDRS or PDQ might have masked the 
medication effect in the ANOVA without covariates, and that the 
effect of levodopa on instrumental learning can only be seen when 
other possible differences between the subgroups are controlled 
for. One possible explanation for the weaker effect in the instru-
mental learning task is that it was relatively simple; participants 
also considered it to be the easier task. Given that there was no 
ceiling effect, such an explanation seems unlikely though. An alter-
native explanation is that participants searched – despite differ-
an optimal adaptation to the environment, in our case the task environ-
ment or the properties of a feedback-based task. Within reward-based 
learning, an important property of a task is the way in which stimuli 
are associated with their respective feedback. These   stimulus-reward 
associations can be either constant over time or dynamic. Dynamic 
reward contingencies are much more exemplary for a “real world” envi-Frontiers in Human Neuroscience  www.frontiersin.org  October 2010  | Volume 4  | Article 169  |  9
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Table 7 | Means and standard deviations for the number of taps in the finger-tapping task for normal controls (NC) and PD patients.
  NC  PD ON  PD OFF    t  df  Sig. 
              (two-tailed)
        Tapping right:
Right hand  118.6 ± 34.5  115.7 ± 38.7  117 .5 ± 39.4  NC vs. ON  0.218  27  0.829
        NC vs. OFF  0.085  27  0.933
        ON vs. OFF  0.331  14  0.745
        Tapping left:
Left hand  115.4 ± 23.6  112.7 ± 38.8  112.5 ± 44.1  NC vs. ON  0.224  27  0.824
        NC vs. OFF  0.223  27  0.825
        ON vs. OFF  −0.035  14  0.973
Independent and paired-samples t-tests were calculated to compare mean number of taps achieved within 30 s.
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FiGure 4 | Scatterplots depicting the relationship between the daily dosage of levodopa taken by PD patients and performance measures on the 
reward-based learning tasks (left: number of reversals achieved in the reversal task, right: percentage correct in the learning task with constant reward 
contingencies).
The inclusion of covariates, however, results in a decreased number 
of degrees of freedom in the statistical analysis. Any future inves-
tigation of the effect of levodopa on simple instrumental learn-
ing would benefit from studying a larger sample of patients with 
better comparable patient subgroups. From the results achieved 
in the present study, we can reason that there is a very strong 
(detrimental) effect of levodopa on feedback-based learning char-
acterized by changing reward contingencies. The effect of levodopa 
on feedback-based learning characterized by constant reward con-
tingencies is less clear. Nevertheless, there is some evidence for a 
beneficial effect of levodopa on this kind of learning, which should 
be investigated further.
ing instructions – for patterns in the reward sequences. When no 
pattern is present, such behavior introduces noise in performance 
scores (Wolford et al., 2004). Due to the weaker effects achieved 
on the instrumental learning task, we suggest that future studies 
should further investigate the effect of levodopa monotherapy on 
learning of constant stimulus-reward associations. Ideally, those 
studies should match ON-beginners and OFF-beginners accord-
ing to clinical features such as UPDRS, Hoehn and Yahr, fatigue, 
depression and quality of life scores. Unfortunately, our patients 
had to be recruited in a consecutive manner, which resulted in 
subgroups that differed on those clinical measures and which in 
turn led us to control for those differences by means of covariates. Frontiers in Human Neuroscience  www.frontiersin.org  October 2010  | Volume 4  | Article 169  |  10
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(1988). This theory predicts that PD patients on dopaminergic 
medication are better at tasks that require dorsal striato-frontal 
structures (which are affected more severely in PD), but perform 
more poorly on tasks requiring the ventral striatum or orbitofrontal 
cortex, parts of the brain that are less severely affected. This is due 
to the “overdosing” effect of dopaminergic medication with DA 
doses necessary to restore DA levels in the dorsal striatum being 
too high for the less affected ventral structures. Evidence for this 
theory comes from a number of studies (e.g., Cools et al., 2001a; 
Mehta et al., 2001). Instrumental learning of constant stimulus-
reward associations has been linked repeatedly to dorsal striatal 
structures (Yin et al., 2004; Kimchi et al., 2009; Shiflett et al., 2010), 
whereas reversal learning has been found to rely on ventral striatal 
(Cools et al., 2002; Heekeren et al., 2007) and ventral prefrontal/
orbitofrontal structures (Rolls, 2000; Xue et al., 2008). By applying 
these findings to our tasks (i.e., dorsal structures underlying the 
instrumental learning task and ventral structures underlying the 
reversal learning task), our results confirm the predictions of the 
“overdose hypothesis”.
On the basis of the “overdose hypothesis”, the framework pro-
vided by Frank and colleagues allows a more detailed interpretation 
of our results (Frank et al., 2004; Frank, 2005). Starting from the 
finding that PD patients off medication learn better from negative 
feedback, whereas medicated patients are better able to learn from 
positive feedback, the theory emphasizes the relevance of a large 
dynamic range of the DA signal for feedback learning. The ability to 
produce DA dips is important for learning from negative feedback, 
whereas the production of DA bursts is crucial for learning from 
positive feedback. Frank et al. (2004) suggest that these abilities are 
impaired in PD patients. Following their argumentation, perform-
ance differences on our reversal learning task can be explained in 
terms of learning from negative feedback: Since the aim of the 
reversal task was to find out the highest-rewarded option at any 
moment in the course of the experiment, choices for the formerly 
“good” option resulted in bad outcomes after the occurrence of a 
reversal, which, in turn, signaled the need to switch choice behavior. 
Even though feedback was in the positive range only (i.e., there 
were no negative points or “losses”), outcomes lower than out-
come expectations result in negative prediction errors (Hollerman 
and Schultz, 1998; Bayer and Glimcher, 2005) and are perceived 
as negative feedback. According to the framework of Frank et al. 
(2004), DA overdosing of task-relevant ventral structures hinders 
the effectiveness of phasic DA dips in bringing DA levels below 
the threshold necessary for learning from negative feedback. In 
contrast, unmedicated patients with near-normal DA levels in 
ventral striato-frontal structures are able to produce effective DA 
dips in response to negative prediction errors. The higher DA lev-
els of medicated patients would be advantageous in the simpler 
instrumental learning task, where subjects have to rely on positive 
prediction errors to learn which of two alternatives is more benefi-
cial. Accordingly, unmedicated patients perform worse in this task 
due to their decreased DA levels in the task-relevant dorsal striatal 
structures, which make DA bursts less effective.
The DA “denervation hypothesis” (e.g., Kulisevsky, 2000) has 
been brought up as an alternative explanation of medication-
dependent differences in task performance. According to this 
hypothesis, levodopa-induced cognitive impairment depends on 
We tested a group of healthy volunteers in addition to the patient 
sample to explore how patients on and off levodopa compare to 
normal control subjects on our two reward-based tasks. When 
pooled together, PD patients did not differ significantly from the 
control group on the reward-based tasks. In the case of the reversal 
learning task, this finding is not surprising as performance of con-
trols lay in between that of patients on and patients off medication. 
This might suggest that the PD patients’ performance is in the same 
range as that of healthy elderly subjects, a finding that is in line 
with previous studies which did not report a difference between 
the performance of PD patients and elderly control subjects on 
feedback-based tasks (e.g., Schmitt-Eliassen et al., 2007). With 
regard to the simple instrumental learning task, we suppose that 
different factors have contributed to the lacking group differences. 
Despite a tendency of controls to perform best and PD patients off 
medication to perform worst, none of the group comparisons were 
significant. One reason might be that the instrumental learning 
task was comparatively easy. Furthermore, our sample size was 
relatively small and our PD patients were only mildly to moder-
ately affected by PD (Hoehn and Yahr score < 4). In addition, most 
patients had relatively short disease and symptom durations. This is 
reflected in the fact that we did not find any group differences with 
regard to reaction times or trial omissions in either task nor did we 
find significant differences on the finger-tapping task conducted 
to control for performance differences due to motor impairments. 
More pronounced performance differences might be detected in 
later stages of the disease.
Similarly, we found no significant correlations between the levo-
dopa dose and any of the reward-based learning tasks, neither in the 
“ON” nor in the “OFF” condition. This is in accord with a study by 
Jahanshahi et al. (2010) who reported that the levodopa equivalent 
dose in their PD patients and the performance on a probabilistic 
classification paradigm were not significantly correlated.
We tested the control subjects only once. Since our patients were 
tested twice (once on, once off medication), a better comparison 
between patients and control subjects would have been possible if 
we had tested the controls twice as well. Because our focus lay on 
the comparison of the different medication states of the patients, 
we attempted to minimize the influence of a potential practice 
effect by dividing the patient sample into two subgroups – one 
starting off levodopa, the other one on levodopa – and thereby 
evening out the session effect across medication states. The fact 
that we found significant group × session interactions for the “ON 
first” and “OFF first” subgroups, despite potential learning effects 
that might have occurred on the second assessment, argues for 
the strength of our findings. If a subgroup performs worse on the 
second session (which was the case for the OFF-beginners on the 
reversal   learning task and for the ON-beginners on the instru-
mental learning task) even though one might expect an advantage 
with increasing practice, it emphasizes the strong influence of the 
dopaminergic medication on the task performance. Nevertheless, 
it is advisable for future studies with a similar design to test both 
the patients and the control group twice to allow for a better com-
parison between those groups.
The double dissociation between medication state and perform-
ance in two reward-based learning tasks is compatible with the 
“overdose hypothesis”, a theory first expressed by Gotham et al. Frontiers in Human Neuroscience  www.frontiersin.org  October 2010  | Volume 4  | Article 169  |  11
Graef et al.  Dopaminergic influence on reward-based learning
prediction error (Schultz and Dickinson, 2000). This should result 
in a narrower range of DA firing and a consecutive impairment 
to reach the thresholds necessary for learning both from positive 
and negative feedback in PD patients treated with a DA agonist. 
Accordingly, even in healthy subjects, administration of DA agonists 
impairs performance both in simple instrumental learning tasks 
with constant stimulus-reward associations and reversal learning 
(e.g., Mehta et al., 2001; Pizzagalli et al., 2008; Boulougouris et al., 
2009; Haluk and Floresco, 2009; Santesso et al., 2009). As a conse-
quence, in contrast to levodopa, DA agonists would be expected 
to impair performance on our instrumental learning task, a task 
relying on positive feedback, i.e., phasic DA bursts.
The differing medication might explain some inconsistencies 
between beneficial medication (levodopa monotherapy) effects on 
our instrumental learning task and detrimental medication (levo-
dopa plus other antiparkinsonian drugs) effects on instrumental 
paradigms in PD patients (Shohamy et al., 2006; Jahanshahi et al., 
2010). However, a closer look at those studies reveals that the tasks 
conducted are not quite comparable to our tasks. For instance, 
a recent study by Jahanshahi et al. (2010) found PD patients on 
medication to be impaired on the WPT. Knowlton et al. (1996) had 
associated the WPT with the dorsal striatum. Therefore, the find-
ings by Jahanshani et al. (2010) seem to contradict our result that 
the performance on a task linked to dorsal striato-frontal circuitry 
is improved on medication. However, the authors cite evidence 
from an imaging task that found ventral striatal activations during 
a parallel version of the WPT (Rodriguez et al., 2006). Considering 
this evidence, the results are in agreement with our finding that 
medicated patients are impaired on a task associated with ventral 
striato-frontal circuitry. Another study seems to contradict our 
finding of enhanced instrumental learning on levodopa. In this 
study, PD patients on levodopa were found to be impaired on a 
two-phase learning and transfer task (Shohamy et al., 2006). In the 
first phase, the subjects learned a concurrent discrimination. For 
eight discrimination pairs, they had to find out which of the two 
objects within each pair was the rewarded one. When compared to 
patients off levodopa, medicated patients performed worse. This 
seems to argue against our findings. Yet, the task used in that study 
is also unlike our instrumental learning task. The main difference 
is that the task used by Shohamy et al. (2006) was characterized by 
a higher memory load because the discrimination pairs were not 
presented consecutively but rather in a concurrent fashion. When 
tested on a version of the task with reduced memory load, i.e., when 
the discrimination pairs were presented successively, as was the case 
in our instrumental learning task, PD patients on levodopa were 
not impaired anymore compared to healthy control subjects. This 
suggests that the working memory requirements of a task influ-
ence performance on reward-based tasks as well. Unfortunately, 
patients off levodopa were not tested on this reduced memory load 
version of the task.
Similar relationships between subcortical DA action and per-
formance in reward-based learning tasks have been shown for 
both genetically determined interindividual differences in healthy 
subjects and differences imposed by pharmacological challenge of 
healthy subjects. Pessiglione et al. (2006) found enhanced reward-
based performance when administering levodopa, but impaired 
performance  in  a  simple  probabilistic  instrumental  learning 
the extent of DA cell loss in particular brain sites. The theory states 
that “frontal” disturbances occur only after a massive degenera-
tion of the DA system. Consequently, “overdose hypothesis” and 
“denervation hypothesis” make different assumptions in regard 
to the role of disease severity in DA-related cognitive impairment. 
Whereas the “overdose hypothesis” predicts greater impairment 
upon DA administration in less affected patients, the “denervation 
hypothesis” opts for a more marked impairment in the severely 
affected. Since we tested patients with relatively short symptom 
and disease durations that suffered from mild to moderate PD, 
our data do not allow drawing conclusions about reward-based 
learning impairments in severely affected patients. However, since 
a large dynamic range of the DA signal has been emphasized to 
be needed for the appropriate weighting of feedback (Frank et al., 
2004), it is conceivable that along with progressive cell loss in 
ventral striato-frontal loops, DA medication might not be able 
to restore firing patterns needed to effectively encode learning 
signals in reversal learning. Therefore, the “overdose hypothesis” 
and the “denervation hypothesis” might be less contradictory than 
it seems at first glance, especially in later stages of the disease. 
Further research is needed to evaluate to what extent dopamin-
ergic medication exerts beneficial or detrimental effects on func-
tions relying on ventral striato-frontal circuits in advanced stages 
of the disease.
One advantage of the present study is the within-subject design 
that was used to compare the different medication states in PD. Due 
to the within-subject design, it is coherent that our results can be 
ascribed to DA availability and not to other pre-existing group dif-
ferences that might have existed between groups in between-subject 
designs. That our patients received levodopa monotherapy has to be 
mentioned as an additional advantage. We included only patients 
on levodopa to avoid heterogeneity in the dopaminergic treatment. 
Some of the studies concerned with reward-based performance in 
PD have investigated patients that were not exclusively treated with 
levodopa (e.g., Shohamy et al., 2006; Jahanshahi et al., 2010), thus 
bearing the risk of confounds. DA agonists have different pharma-
cological properties than levodopa. Since levodopa is a precursor 
to DA, it influences both tonic and phasic DA transmission (see 
Breitenstein et al., 2006). It is taken up by dopaminergic neurons 
and, after conversion to DA, can be released into the synaptic cleft 
in a stimulation-  dependent manner. DA agonists are not taken 
up by DA neurons and thus do not increase presynaptic DA avail-
ability and cannot be released phasically. Instead, they exert their 
DA-mimicking function through binding to postsynaptic DA recep-
tors and thereby influence tonic DA levels. This change in tonic DA 
is believed to reduce the effect of phasic, stimulation-dependent 
endogenous DA release (Breitenstein et al., 2006). Consequently, 
while levodopa allows or even boosts phasic DA bursts and dips 
while simultaneously raising tonic DA levels, DA agonists only 
increase tonic DA levels. DA agonists act tonically on postsynaptic 
receptors of the D1 or D2 type, but also on presynaptic D2-like 
autoreceptors. For that reason, different mechanisms of action 
are possible: either, occupation of postsynaptic DA receptors may 
reduce the neurotransmission of phasic postsynaptic DA signals, 
or stimulation of sensitive presynaptic autoreceptors may reduce 
DA release and thus phasic DA signaling (Breitenstein et al., 2006; 
Cools, 2006), e.g., the phasic bursts believed to encode the reward Frontiers in Human Neuroscience  www.frontiersin.org  October 2010  | Volume 4  | Article 169  |  12
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By showing a detrimental effect of levodopa on the perform-
ance in a reward-based learning task characterized by dynamic 
reward contingencies (and associated with ventral striato-frontal 
circuitry) and a beneficial effect on the performance in a task char-
acterized by constant reward contingencies (associated with dor-
sal striato-frontal circuitry), the present study demonstrates in a 
within-subject design that reward-based task performance differs 
depending on the availability of levodopa, on specific features of 
the task (stimulus-reward contingencies) as well as on underlying 
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